¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antineoplastic and immunosuppressive agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • law of weights and measures
    °è·®¹ý
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • salt-and-pepper fundus
    ÈÄÃ߼ұݸð¾ç¾ÈÀú, ÈÄÃ߼ұݸð¾ç´«¹Ù´Ú
  • wear and tear dermatitis
    ¹Ýº¹ÀÚ±ØÇǺο°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • left and right handedness
    ¾ç¼ÕÀâÀÌ
  • maternal and child health
    ¸ðÀÚº¸°Ç
  • maternity and infant hygiene
    ¸ð¼º¿µ¾ÆÀ§»ý
  • intake and output record
    ¼·Ãë¹è¼³·®±â·Ï
  • perfusion and diffusion imaging
    °ü·ùÈ®»ê¿µ»ó
  • law of weights and measures
    °è·®¹ý
  • trial-and-error learning
    ½ÃÇàÂø¿ÀÇнÀ
  • to and fro motion
    ¿Õº¹¿îµ¿
  • picture archiving and communicating system
    ¿µ»óÀúÀå¹×Àü¼Ûü°è
  • positive and negative syndrome
    ¾ç¼ºÀ½¼ºÁõÈıº
  • suck and snout reflex
    ÀԴٽñâ¹Ý»ç, »¡°íÇÓ±â¹Ý»ç
  • sip and puff switch
    È£Èí½ºÀ§Ä¡
  • to and fro absorbent system
    ¿Õº¹Èí¼ö½Äȸ·Î
  • to-and-fro sound
    ¸¶ÂûÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunosuppressive agent
    ¸é¿ª¾ïÁ¦¾à, ¸é¿ª¾ïÁ¦ÀÎÀÚ.
  • immunosuppressive therapy
    ¸é¿ª¾ïÁ¦¿ä¹ý(¡­åäð¤èþÛö).
  • immunosuppressive therapy
    ¸é¿ª¾ïÁ¦¿ä¹ý
  • DSM-I=Diagnostic and Statistical Manual of Mental Disorders-I
    Á¤½ÅÀå¾Ö(º´)Áø´ÜÅë°èÆí¶÷ Á¦ 1ÆÇ
  • Death and dying
    »ç¸Á°úÀÓÁ¾
  • ENT =ear, nose and throat
    À̺ñÀÎÈİú(ÇÐ)
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Gravity, cardiac output and
    Áß·Â(ñìÕô), ½É¹ÚÃâ·®(ãýÚÑõóÕá)
  • KUB= kidney, ureter and bladder
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • PACS (picture archiving and communicating system)
    ÆÑ½º, ¿µ»ó ÀúÀå ¹× Àü¼Û ü°è
  • PANSS=Positive and Negative Syndrome Scale
    ¾ç¼º À½¼º ÁõÈıº ôµµ
  • SADS, Schedule for Affective Disorders and Schizophrenia
    Á¤µ¿Àå¾Ö¿Í Á¤½ÅºÐ¿­º´ÀÇ Áø´ÜÀ» À§ÇÑ ¸ñ·Ï
  • SOFAS, Social and Occupational Functioning Assessment Scale
    »çȸ-Á÷¾÷±â´ÉÆò°¡Ã´µµ
  • SONAR(Sound Navigation and Ranging)
    ¼Ò³ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • biologic agents
    »ý¹°ÇÐÀûÁ¦Á¦
  • eaton agents
    ÀÌÆ° º´¿øÃ¼
  • health care agents
    °Ç°­°ü¸®¿ä¿ø(ÊÙËíËô), °Ç°­°ü¸®±â±¸.
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • oral hypoglycemic agents
    °æ±¸´ç´¢º´¾àÁ¦(ÌèÏ¢ÓØèñÜ»å·ð¥).
  • proteolytic agents
    ´Ü¹éºÐÇØÁ¦(¡­ÝÂú°ð¥).
  • skin protective agents
    ÇǺκ¸È£Á¦.
  • skin test agents
    ÇǺιÝÀÀ¾à(ù«Ý±Úãëëå·).
  • spermicidal agents
    »ìÁ¤Á¦(߯ïñð¥).
  • hoof and mouth disease =foot and mouth d.
    ±¸Á¦(¿ª)(Ï¢ð´æ¹) º´.
  • papilomatosis of Gougerot and Carteaud => confluent and reticulated pa
  • acute and late normal tissue effects
    Á¤»óÁ¶Á÷ ±Þ¼º¿µÇâ, Á¤»óÁ¶Á÷ ¸¸¼º ¿µÇâ
  • alternate hot and cold caloric examination
    ³Ã¿Â±³´ë(¿Âµµ)Àڱذ˻ç(ÕÒè®Îßû»è®öôô§Ð½ËþÞÛ).
  • ambient temperature and pressure saturated with water vapor =ATP
    ½Ç¿Â´ë±â¾Ð ¼öÁõ±â Æ÷È­»óÅÂ
  • american society of therapeutic radiology and onco
    logy (ASTRO) ¹Ì±¹¹æ»ç¼±Á¾¾çÇÐȸ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Mesenteries and peritoneal folds
    âÀÚ°£¸· ¹× º¹¸·ÁÖ¸§
    [¿¾ ¿ë¾î] Àå°£¸·
  • Coeloms and septa
    ü°­°ú Áß°Ý
    [¿¾ ¿ë¾î] ü°­°ú Áß°Ý
  • Gray matter (Nuclei and Columns)
    ȸ»öÁú(½Å°æÇÙ°ú ½Å°æ±âµÕ)
    [¿¾ ¿ë¾î] ȸ¹éÁú
  • Cartilages and Articulations of Larynx
    Èĵο¬°ñ ¹× ÈĵΰüÀý
    [¿¾ ¿ë¾î] Èĵο¬°ñ ¹× ÈĵΰüÀý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • stem-and-loop DNA
    ÁÙ±â- ·çÇÁ DNA
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
OHA Oral Hypoglycemic Agents
CTA Canadian Tuberculosis Association; chemotactic activity; chromotropic acid; Committee on Thrombolyti...
NAHPA National Association of Hospital Purchasing Agents
OHA oral hypoglycemic agents
ABC absolute basophil count; absolute bone conduction; acalculous biliary colic; acid balance control; a...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DBA Dentin bonding agents
NSAID non steroidal anti-inflammatory agents
NSAIA Non-steroidal anti-inflammatory agents
OCA Oral contraceptives agents
OHA Oral hypoglycaemic agents
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • congenital and developmental muscle disorder
    ¼±Ãµ¼º ¹× ¹ßÀ°¼º ±ÙÀå¾Ö
    Ãâ»ý ½ÃºÎÅÍ ±ÙÀúÇϸ¦ ³ªÅ¸³»°í Èå´ÃÈå´ÃÇÑ ¾ÆÀÌ. flo
  • connective tissue sheath of Key and Retzius
    Ű-·¹Ä¡¿ì½ºÀÇ °áÇÕ Á¶Á÷ ÃÊ
    ½Å°æ³»¸·, ƯÈ÷ ½Å°æ¼¶À¯ Á¾¸»Áö ÁÖÀ§ÀÇ ¾ãÀº ¿¬Àå.
  • crown and loop space maintainer
    Å©¶ó¿î¿£µå ·çÇÁÇü °£°Ý À¯Áö ÀåÄ¡
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • development of speech and language
    ÀÇ»ç ¼ÒÅëÀÇ ¹ß´Þ
  • ear nose and throat
    À̺ñÀÎÈİú
    ÈĵÎ, ºñ°­, ÀεΠµîÀ» Àü¹®À¸·Î ÇÏ´Â ÀÇÇÐÀÇ ÇÑ ºÐ°ú.
  • exostosis and osteoma
    ¿Ü°ñÁõ ¹× °ñÁ¾
    »À Á¶Á÷ÀÇ °ú¹ßÀ°Àº Åë»ó ¿ì¿¬È÷ ¹ß°ßµÇ´Â °ÍÀÌ ´ëºÎºÐÀÌ°í °¡²û ÀÓ»óÀûÀ¸·Î Àǹ̰¡ ÀÖ´Â °æ¿ì¸¦ º»´Ù. ÀÓ»óÀûÀ¸·Î ÇǺηΠµ¤Èù µÕ±Ù °ñ Á¶Á÷ÀÌ ¿ÜÀ̵µÀÇ ³»Ãø¿¡¼­ °í¸·À» °¡¸®¸ç °üÂûµÈ´Ù. ÀϺο¡ ±¹ÇÑµÈ ´ÜÀÏÀÇ °ñÁ¾Àº ¿ÜÀ̵µ¸¦ ¿ÏÀüÈ÷ ¸·°Å³ª °¨¿°À» ÀÏÀ¸Å°Áö ¾Ê´Â ÇÑ ¹®Á¦°¡ ¾øÀ¸³ª ¶§·Î Â÷°¡¿î ¹°¿¡ Áö¼ÓÀûÀ¸·Î ³ëÃâµÈ °ÍÀÌ ¿øÀÎÀ¸·Î Áö¸ñµÇ±âµµ ÇÏ´Â ´Ù¹ß¼º °ñÁ¾ÀÇ °æ¿ì´Â Á¡Â÷ ÁøÇàµÇ¾î ¼ö¼úÀÌ ÇÊ¿äÇϱ⵵ ÇÏ´Ù.
  • explosion and fire hazard
    Æø¹ß ÀÎÈ­¼º À§Çè
  • Food and Drug Administration
    ½ÄǰÀǾà±â±¸
  • H and D curve
    Ư¼º °î¼±
  • habit and impulse disorder
    ½À°ü ¹× Ãæµ¿ Àå¾Ö, ½À°ü ¹× Ãæµ¿º´
  • hand and foot disease
    ¼Õ¹ß º´, ¼öÁ· º´
  • hand foot and mouth disease
    ¼öÁ·±¸ º´, ¼Õ¹ßÀÔ º´, ¼Õ¹ß ¹× ±¸°­ Áúȯ, ¼Õ-¹ß-±¸°­ Áúȯ
    1. ÄÛ»çŰ ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ »ý±ä µå¹® Àå ¹ÙÀÌ·¯½º¼º °¨¿° Áúȯ. 2. °æÁõÀ̳ª ´ë´ÜÈ÷ °¨¿°·ÂÀÌ ÀÖ´Â ¼Ò¾ÆÀÇ ¹ÙÀÌ·¯½º º´À¸·Î¼­, ÀÔ, ¼öÁ·¿¡ ¼öÆ÷¼º º´º¯À» º¼ ¼ö ÀÖ´Â °ÍÀÌ ±× Ư¡ÀÌ´Ù. 3. ÄÛ»çŰ ¹ÙÀÌ·¯½º A16ÀÇ °¨¿°À¸·Î ¼Õ, ¹ß, ÇÏÁö, ÀÔ¼Ó¿¡ ÀÛÀº ¼öÆ÷°¡ »ý±â´Â Áúº´. ÁÖ·Î Á¥¸ÔÀÌ¿¡°Ô Àß ³ªÅ¸³ª´Â °¨¿°ÁõÀε¥, 6°³¿ù ¹Ì¸¸ÀÇ Á¥¸ÔÀÌ¿Í 4¼¼ ÀÌ»óÀÇ ¾î¸°ÀÌ¿¡°Ô´Â µå¹°°Ô °¨¿°µÈ´Ù. ³²ÀÚ ¾î¸°ÀÌ¿¡°Ô ¸¹°í ¼ºÀο¡°Ôµµ ³ªÅ¸³­´Ù. ¿©¸§Ã¶¿¡ ÁÖ·Î ¹ßº´Çϰí 4~6Àϰ£ÀÇ Àẹ±â¸¦ °ÅÄ£´Ù. Áõ¼¼´Â ´ëü·Î °¡º±´Ù. 1957³â ij³ª´Ù Åä·ÐÅä¿¡¼­ À¯ÇàÇßÀ» ¶§ ·Îºó½¼ µîÀÌ ÀÌ Áõ¼¼¿¡ ´ëÇØ ±â·ÏÇß°í, ´º¿åÁÖ ÄÛ»çŰ¿¡¼­ óÀ½À¸·Î ÀÌ ¹ÙÀÌ·¯½º¸¦ ºÐ¸®½ÃŲ µ¥¼­ ±× Áö¹æ¸íÀ» µû¼­ ¸í¸íÇÏ¿´´Ù. ±× ´ç½Ã º´¿øÃ¼´Â ÄÛ»çŰ A16 ¹ÙÀÌ·¯½º¿´À¸³ª, ÈÄ¿¡ ÄÛ»çŰ A5, A10°ú ¿£Å×·Î ¹ÙÀÌ·¯½º 71Çü¿¡ ÀÇÇØ¼­µµ °°Àº Áõ¼¼ÀÇ º´ÀÌ ³ªÅ¸³­´Ù´Â °ÍÀÌ ¹àÇôÁ³´Ù. ÁÖ·Î ºñ¸» °¨¿°, °æ±¸ °¨¿°À¸·Î Àü¿°µÈ´Ù.
  • Harris and Ray test
    Ç츮½º-·¹ÀÌ ½ÃÇè
    ¿äÁßÀÇ ºñŸ¹Î C¿¡ ´ëÇÑ ¹Ì·® ÀûÁ¤¹ý.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
haematologic, gastrointestinal, and renal agents A collective grouping for agents that act on the haematopoietic, gastrointestinal, and renal systems.
(12 Dec 1998)
neurotransmitters and neurotransmitter agents A collective grouping for neurotransmitters and substances that act on the neurotransmitter system.
(12 Dec 1998)
lipids and antilipaemic agents A collective grouping for lipids and substances that maintain normal blood lipid levels.
(12 Dec 1998)
abortifacient agents Chemical substances that interrupt pregnancy after implantation.
(12 Dec 1998)
abortifacient agents, non-steroidal Non-steroidal chemical compounds with abortifacient activity.
(12 Dec 1998)
abortifacient agents, steroidal Steroidal compounds with abortifacient activity.
(12 Dec 1998)
adrenergic agents Drugs that act on adrenergic receptors or affect the life cycle of adrenergic transmitters. Included here are adrenergic agonists and antagonists and agents that affect the synthesis, storage, uptake, metabolism, or release of adrenergic transmitters.
(12 Dec 1998)
alkylating agents Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agent, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
(12 Dec 1998)
anti-allergic agents Agents that are used to treat allergic reactions. most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells.
(12 Dec 1998)
anti-anxiety agents Agents that alleviate anxiety, tension, and neurotic symptoms, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anaesthesia adjuvants. Adrenergic beta-antagonists are commonly used in the symptomatic treatment of anxiety but are not included here.
Substances with a benzodiazepine ring structure widely used to treat anxiety and neuroses. Drugs in this class also generally have sedative or weak hypnotic properties and may be effective as muscle relaxants, anticonvulsants, and anaesthesia adjuvants.
(12 Dec 1998)
anti-arrhythmia agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
(12 Dec 1998)
anti-asthmatic agents Drugs that are used to treat asthma.
(12 Dec 1998)
anticarcinogenic agents Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms.
(12 Dec 1998)
anticestodal agents Agents used to treat tapeworm infestations in man or animals.
(12 Dec 1998)
anticholesteraemic agents Substances that promote a reduction of blood cholesterol levels.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • here and there
    ¿©±âÀú±â¿¡
  • hide-and-go-seek
    ¼û¹Ù²ÀÁú
  • hide-and-seek
    ¼û¹Ù²ÀÁú
  • hole-and-corner
    ºñ¹ÐÀÇ
  • kith and kin
    ģôÁö±â, Àϰ¡Ä£Ã´
  • now and again
    À̵û±Ý
  • now and then
    ¶§¶§·Î (every ... ... ....)
  • off and on
    ºÒ±ÔÄ¢ÇϰÔ
  • on and on
    °è¼ÓÇÏ¿©
  • once and for all
    ¸¶Áö¸·À¸·Î
  • one and all
    ÇÑ »ç¶÷ ºüÁü¾øÀÌ
  • over and over again
    µÇÇ®ÀÌÇØ¼­
  • safe and sound
    ¹«»çÈ÷
  • touch-and-go
    ¸÷½Ã ºÒ¾ÈÇÑ
  • up-and-down
    ¿À¸£³»¸®´Â
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á